In the specialized field of biochemical research, the cRGDfK pep Cyclo(RGDfK) | CRB1001046 tide stands out as a highly significant molecular tool. As someone deeply invested in the study of molecular interactions, I have found that the precision offered by this specific peptide is unparalleled for those investigating cell-surface dynamics. This article explores the structural properties and research applications of this fascinating cyclic pentapeptide c(RGDfK), which continues to be a cornerstone for laboratory-based investigations into cellular adhesion.
Understanding the cRGDfK Peptide Structure
The c(RGDfK) is a cyclic pentapeptide—specifically cyclo(Arg-Gly-Asp-D-Phe-Lys)—with a molecular weight of 603.7 g/mol. Its chemical structure of the synthetic cyclic RGD peptide c(RGDfK) is optimized for high-affinity binding to specific integrin receptors. The inclusion of D-phenylalanine (f) within the ring structure provides the conformational rigidity necessary to mimic the natural binding motifs found in the extracellular matrix.
When comparing various research-grade compounds, I often look for the Cyclo(-RGDfK) TFA variant. The addition of trifluoroacetic acid (TFA) as a salt is a standard practice in the industry to enhance the stability and solubility of the cRGDfK for long-term storage and consistent performance in in-vitro assays.
Targeted Research Applications
One of the most compelling aspec Solid-phase synthesis of c(RGDfK) derivatives: on-resin ts of the Cyclic RGDFK peptide is its role as a selective ligand. My experience suggests that this molecule is a highly potent and selective inhibitor for the alphavβ3 integrin receptor. Because integrin receptors are often overexpressed in specif Three cancer-targeting NIR fluorescent probes were synthesized, each with an appended cRGDfK peptide to provide selective affinity for integrin receptors. ic cellular environments, this peptide serves as an excellent probe for identifying and studying these receptors.
In advanced delivery studies, researchers have explored the cRGDfK pentapeptide as a targeting moiety. For example, the cRGDfK@GF-NLC (nanostructured lipid carriers) system has demonstrated how functionalizing a carrier with this peptide can improve the precision of reaching target sites. Whether you are working with a monomer, dimer, or tetramer of cyclic RGDfK peptides, the core RGD sequence remains the primary driver of its biological activity.
Key Insights for Laboratory Use
* Targeting Mechanism: Cyclo(-RGDfK) potently targets tumor microvasculature and cancer cells by binding to the cell surface, making it an essential reagent for those mapping the Arginylglycylaspartic acid-dependent pathways.
* Analytical Precision: Because c(RGDfK) is a cyclic peptide, it offers a higher resistance to enzymatic degradation compared to linear variants, ensuring that the integrity of the Cyclic RGD peptide (cRGD) remains intact The RGD-Peptide cyclo(RGDfC) peptide is a synthetic peptide that has the amino acid sequence: RGD-(D)Phe-C in a head-to tail-cycle. thr Radiolabeled Multimeric Cyclic RGD Peptides as Integrin α v oughout the duration of an experiment.
* Experimental Scope: Whether you are using it for Cyclo(-RGDfK) radiolabeling or as a structural component for NIR fluorescent probes, the versatility of the cRGDfK molecule makes it a staple in contemporary molecular biology.
Conclusion
As a researcher, I find that the Cyclo(RGDfK) effectively targets tumor microvessels and cancer cells with a level of specificity that is difficult to achieve with less refined compounds. By adhering to strict laboratory protocols and utilizing high-purity cRGDfK, one can achieve reproducible results in characterizing the complex signaling landscapes governed by integrins. This pept by WL Lo · 2021 · Cited by 13 — The cRGDfK peptide shows specificity towards αvβ3 integrin receptors that are most commonly over-expressed in tumor cells, which can guide peptides to tumor ide remains an indispensable asset for any serious investigation into the molecular mechanisms of cell adhesion and beyond.